ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR and INFECTIVE PULMONARY EXACERBATION OF CYSTIC FIBROSIS

Overview

INFECTIVE PULMONARY EXACERBATION OF CYSTIC FIBROSIS is the #1 most commonly reported adverse reaction for ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR, manufactured by Vertex Pharmaceuticals Incorporated. There are 777 FDA adverse event reports linking ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR to INFECTIVE PULMONARY EXACERBATION OF CYSTIC FIBROSIS. This represents approximately 4.0% of all 19,269 adverse event reports for this drug.

Patients taking ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR who experience infective pulmonary exacerbation of cystic fibrosis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

INFECTIVE PULMONARY EXACERBATION OF CYSTIC FIBROSIS is moderately reported among ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR users, representing a notable but not dominant share of adverse events.

Other Side Effects of ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR

In addition to infective pulmonary exacerbation of cystic fibrosis, the following adverse reactions have been reported for ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR:

• HEADACHE — 747 reports
• COUGH — 579 reports
• ANXIETY — 575 reports
• RASH — 560 reports
• PRODUCTIVE COUGH — 519 reports
• FATIGUE — 513 reports
• WEIGHT INCREASED — 494 reports
• CYSTIC FIBROSIS — 475 reports
• ABDOMINAL PAIN UPPER — 460 reports
• DEPRESSION — 418 reports

Other Drugs Associated with INFECTIVE PULMONARY EXACERBATION OF CYSTIC FIBROSIS

The following drugs have also been linked to infective pulmonary exacerbation of cystic fibrosis in FDA adverse event reports:

Does ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR cause INFECTIVE PULMONARY EXACERBATION OF CYSTIC FIBROSIS?

INFECTIVE PULMONARY EXACERBATION OF CYSTIC FIBROSIS has been reported as an adverse event in 777 FDA reports for ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is INFECTIVE PULMONARY EXACERBATION OF CYSTIC FIBROSIS with ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR?

INFECTIVE PULMONARY EXACERBATION OF CYSTIC FIBROSIS accounts for approximately 4.0% of all adverse event reports for ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR, making it one of the most commonly reported side effect.

What should I do if I experience INFECTIVE PULMONARY EXACERBATION OF CYSTIC FIBROSIS while taking ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR?

If you experience infective pulmonary exacerbation of cystic fibrosis while taking ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

Related Pages